vTv Therapeutics (VTVT) Earnings Date & Reports

Key Takeaways

• vTv Therapeutics (VTVT) is expected to report third-quarter 2026 results around early-to-mid November, with a consensus loss of roughly $1.07 per share (EPS).
• Revenue expectations remain minimal for a development-stage biotech, with analysts modeling only a few hundred thousand dollars for the quarter.
• Investor focus is likely to center on cash runway, research and development (R&D) spending, and progress on lead candidate cadisegliatin (TTP399) for type 1 diabetes.
• In the same quarter a year ago, the company reported a loss of $1.08 per share, setting a relatively flat comparison baseline.
• Historically, VTVT shares have shown outsized, often volatile moves around earnings announcements, reflecting the high sensitivity of small-cap biotech valuations to pipeline news.
• For more detail on the ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore these additional pages.
• Investors seeking automated market ideas can also explore Trending AI Robots for AI-driven trading strategies.

Earnings Context and Why It Matters

vTv Therapeutics is a clinical-stage biopharmaceutical company developing oral small-molecule treatments for diabetes and other chronic diseases. Its lead candidate, cadisegliatin (TTP399), is a liver-selective glucokinase activator in late-stage development for type 1 diabetes. Because the company generates little or no recurring product revenue, quarterly earnings serve less as a measure of profitability and more as a snapshot of clinical progress, spending discipline, and financial runway. With a relatively small analyst following, reported losses and balance-sheet commentary can drive meaningful swings in the share price. For investors, this report offers a key checkpoint on whether the company has sufficient capital to advance its pipeline toward key milestones.

Earnings Expectations

Analysts expect vTv Therapeutics to report a net loss of approximately $1.07 per share for the third quarter of 2026, according to consensus estimates. Revenue is projected to remain minimal, with forecasts clustered around a few hundred thousand dollars, consistent with a company that has yet to commercialize a product. By comparison, vTv reported a loss of $1.08 per share in the third quarter of 2025, meaning the year-over-year comparison is expected to be roughly flat.

It is important to distinguish recurring results from one-time items. In the first quarter of 2026, the company reported positive EPS of $1.65 and revenue of roughly $36.8 million, figures driven largely by non-recurring items rather than sustainable product sales. The most recent quarter, ended June 30, 2026, returned to a reported loss of approximately $1.05 per share, missing consensus. Investors should therefore treat headline EPS volatility cautiously and focus instead on operating expenses, cash and equivalents, and any updates on clinical timelines.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF (exchange-traded fund) discovery tool that helps traders and investors filter the market using technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs with customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking names like vTv Therapeutics across the biotechnology space, the AI Screener can support a more systematic approach to narrowing the field. Explore the AI Screener to refine your market research.

Market Reaction and Investor Sentiment

Sentiment heading into the third-quarter report reflects the broader caution surrounding clinical-stage biotechs. With limited revenue and a heavy reliance on external financing, vTv's share price remains sensitive to any signal about clinical milestones or capital adequacy. Past earnings announcements have produced notably large price swings in both directions, underscoring how much weight investors place on even modest updates. Key risk factors include the potential for higher-than-expected R&D spending, dilution from future capital raises, and any delays in the cadisegliatin development program. As a result, market participants will likely scrutinize the earnings call for forward-looking commentary as closely as the reported numbers themselves.

Forward Outlook and Key Factors to Monitor

Following the third-quarter report, investors should watch several forward-looking indicators. The first is the company's cash position and its stated runway, which will clarify how long current resources can fund operations before additional capital may be needed. For a pre-revenue biotech, this is often the single most important factor influencing near-term valuation.

Second, monitor any updates on cadisegliatin (TTP399) and its Phase 3 development pathway for type 1 diabetes. Changes to enrollment timelines, trial endpoints, or regulatory interactions can materially affect the investment thesis.

Third, pay attention to R&D expense trends. Sustained increases may signal deeper investment in the pipeline, while sharp reductions could reflect cost-cutting that delays clinical progress.

Finally, broader industry conditions in the diabetes and metabolic disease sector, including competitive developments and financing appetite for small-cap biotechs, may shape how investors interpret the company's outlook in the quarters ahead. As always, these considerations are informational and do not constitute investment advice.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations